Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5946
    -0.0004 (-0.06%)
     
  • NZD/EUR

    0.5554
    +0.0014 (+0.25%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.77
    +0.20 (+0.24%)
     
  • GOLD

    2,350.20
    +7.70 (+0.33%)
     
  • NASDAQ

    17,757.86
    +327.35 (+1.88%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,296.04
    +210.24 (+0.55%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.7700
    +1.2740 (+1.38%)
     

Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver

In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.